Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.

Chronic myelomonocytic leukemia (CMML) SEER outcomes registry survival

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
15 Sep 2023
Historique:
medline: 16 9 2023
pubmed: 16 9 2023
entrez: 15 9 2023
Statut: aheadofprint

Résumé

Outcomes for chronic myelomonocytic leukemia (CMML) are insufficiently characterized at the population level. We analyzed epidemiological trends for patients between 2001 and 2017, focusing on age, sex, race, and long-term survivors. Using the Surveillance, Epidemiology, and End Results Program, we studied 3929 patients, in four time-period (tp) cohorts, based on year of diagnosis [2001-2004 (tp1); 2005-2009 (tp2); 2010-2013 (tp3); 2014-2017 (tp4)]. Stable incidence overall, male predominance, and higher incidence for White versus Black and 'Other' races were noted. Three-year relative survival (RS) increased from 27.9% to 36.9% between tp1 and tp4. The most pronounced increase occurred between tp1 and tp2. All subgroups generally experienced RS improvements over time, except notably Black patients. Improvements for patients aged 85+ (3-year RS 8.4-23.6% between tp1 and tp4) and increases in long-term survivors (5-year OS from 13.2-22.3%) were observed. Additional study is warranted to explore these associations, particularly for Black patients.

Identifiants

pubmed: 37715313
doi: 10.1080/10428194.2023.2252123
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Auteurs

Arnaud Lesegretain (A)

Harvard Medical School, Boston, MA, USA.
Daiichi Sankyo, Basking Ridge, NJ, USA.

Andrew Brunner (A)

Massachusetts General Hospital, Boston, MA, USA.

Aziz Benzohra (A)

Daiichi Sankyo, Basking Ridge, NJ, USA.

Amir T Fathi (AT)

Massachusetts General Hospital, Boston, MA, USA.

Classifications MeSH